NCT03590119View on ClinicalTrials.gov

Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 1, 2018

Primary Completion Date

September 1, 2022

Study Completion Date

September 1, 2022

Conditions

Neuroendocrine TumorsLiver Metastases

Interventions

DRUG

Lutetium Lu 177-DOTATATE

Intra-arterial infusion of Lu-177-DOTATATE

Trial Locations (3)

Unknown

Antoni van Leeuwenhoek Cancer Institute, Amsterdam

Erasmus MC, Rotterdam

University Medical Center Utrecht, Utrecht

All Listed Sponsors

lead

Marnix Lam

OTHER

NCT03590119 - Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases | Biotech Hunter | Biotech Hunter